There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS), CytomX Therapeutics Inc (CTMX) and Aslan Pharmaceuticals Ltd (ASLN) with bullish sentiments.
Clovis Oncology (CLVS)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology, with a price target of $36. The company’s shares closed on Friday at $14.78, close to its 52-week low of $11.50.
White commented:
“We reiterate our $36 price target which we derive from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 47.2% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
Currently, the analyst consensus on Clovis Oncology is a Moderate Buy with an average price target of $26.43.
See today’s analyst top recommended stocks >>
CytomX Therapeutics Inc (CTMX)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on CytomX Therapeutics Inc, with a price target of $23. The company’s shares closed on Friday at $9.66, close to its 52-week low of $8.94.
Selvaraju wrote:
“We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $807M, or a price per share of $23, assuming 46.9M shares outstanding and roughly $271M in cash and equivalents as of end-1Q20.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.7% and a 24.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on CytomX Therapeutics Inc is a Strong Buy with an average price target of $20.50, representing an 112.2% upside. In a report released yesterday, Cowen & Co. also initiated coverage with a Buy rating on the stock.
Aslan Pharmaceuticals Ltd (ASLN)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals Ltd, with a price target of $8.50. The company’s shares closed on Friday at $2.91, close to its 52-week low of $2.51.
Chen noted:
“Our 12-month price target is based on an estimated market value of the firm at $294M. This includes a discounted cash flow analysis based asset value of $308M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate, excluding $14M debt and assuming 170.2M shares outstanding at the end of 1Q20. Our probabilities of success are 65% for varlitinib in global BTC (50% in in AML.”
According to TipRanks.com, Chen is ranked #5030 out of 5164 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals Ltd with a $8.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
